SomaLogic sees record sales in 2021 but nearly doubles losses

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public last year in a merger with a special purpose acquisition company, grew sales in 2021 by nearly 50% year over year, but also nearly doubled its losses.

The company posted revenues of $81.6 million, up 46.1% over 2020. That’s a company record and well ahead of guidance provided in previous quarters. 

Net loss was $87.5 million, or a loss of 64 cents per share, as compared to a net loss of $53 million, or 81 cents per share in the prior year.

For the fourth quarter, Somalogic posted a…